Alkermes (ALKS) News
NASDAQ: ALKSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
44.94-1.24 (-2.69%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ALKS news summary
We found 8 recent headlines mentioning Alkermes (ALKS): 0 in the past week and 4 in the past 30 days, most often from Nasdaq, Business Wire. For price context, ALKS is down 2.69% at $44.94. The most recent story, "Alkermes plc Enters Settlement Agreement With Teva Over LYBALVI Patent Litigation", was published by Nasdaq on Nov 12, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Alkermes headlines
- Alkermes plc Enters Settlement Agreement With Teva Over LYBALVI Patent LitigationOn November 6, 2026, Alkermes, Inc. and Alkermes Pharma Ireland Limited, two wholly-owned indirect subsidiaries of Alkermes plc, entered into a Confidential Settlement and License Agreement with Teva…Nasdaq
- Alkermes (ALKS) Surpasses Q3 Earnings and Revenue EstimatesAlkermes (ALKS) delivered earnings and revenue surprises of +212.50% and +3.05%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?NasdaqALKS, ROIV
- Alkermes plc Reports Third Quarter 2026 Financial ResultsDUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended September 30, 2026. To view the detailed third quarter 2026 earnings press release and…Business Wire
- Alnylam Pharmaceuticals (ALNY) Q3 Earnings and Revenues Top EstimatesAlnylam (ALNY) delivered earnings and revenue surprises of +642.47% and +0.63%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?NasdaqALNY, ALKS
- Alkermes to Report Third Quarter Financial Results on November 3, 2026DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Tuesday, November 3, 2026 to discuss the company’s third…Business Wire
- HRMY Stock Gains 27.6% in Six Months: Is There More Room for Growth?Harmony Biosciences gains 27.6% in six months as Wakix sales surge and pipeline advances, with new formulations and clinical milestones offering further growth opportunities.NasdaqHRMY, ALKS, JAZZ
- 4 CNS Drug Stocks Worth Watching This World Mental Health DayAXSM, NBIX, ALKS and ACAD are advancing CNS treatments for mental health disorders, with growing product sales, pipeline progress and new growth opportunities.NasdaqALKS, NBIX, ACAD, AXSM
- Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290ALKS posts positive Phase I data for ALKS 7290, showing meaningful improvements in ADHD symptoms across dose levels in healthy volunteers and adults.NasdaqALKS, RGEN, PGEN